BR1019
- Generic Name
- BR1019
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
Phase 1
Completed
- Conditions
- Essential HypertensionType 2 Diabetes
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT06636877
- Locations
- π°π·
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
Phase 1
Completed
- Conditions
- Type 2 Diabetes MellitusEssential Hypertension
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT06226727
- Locations
- π°π·
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath